D. Pouessel

S. Culine, V. Meignin, P. de Cremoux, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

A. Broeks, Y. Lotan, Y. Allory, 2021, Urologic Oncology: Seminars and Original Investigations.

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2020 .

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

N. Agarwal, C. Sternberg, D. Petrylak, 2022, Journal of Clinical Oncology.

700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2021, Annals of Oncology.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

T. H. van der Kwast, S. Culine, A. Broeks, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA).

M. Maio, P. Barthélémy, A. Necchi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients

B. Klein, J. Daurès, D. Pouessel, 2006, Bone Marrow Transplantation.

Very Fast Recovery of Acute Disseminated Intravascular Coagulation with Abiraterone Acetate in a Patient with Bone Metastases from Castrate-Resistant Prostate Cancer

S. Culine, D. Pouessel, H. Gauthier, 2014, Case Reports in Oncology.

Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis

D. Pouessel, U. Schick, E. Cohen-Jonathan Moyal, 2020, Cancers.

New therapies in renal cell carcinoma

J. Patard, S. Culine, D. Pouessel, 2007, Current opinion in supportive and palliative care.

Hepatic metastases from carcinomas of unknown primary site.

S. Culine, M. Ychou, D. Pouessel, 2005, Gastroenterologie clinique et biologique.

Concomitant Bifocal Urothelial Carcinoma and Breast Tumor: Second Primary Cancer or Metastatic Spread to the Breast?

S. Culine, P. de Cremoux, D. Pouessel, 2014, Case reports in oncological medicine.

Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.

S. Culine, D. Pouessel, N. D. de Champfleur, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.

S. Culine, D. Pouessel, C. Delbaldo, 2012, Anticancer research.

Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site

S. Culine, F. Pinguet, M. Ychou, 2004, Cancer.

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

I. Sobhani, S. Culine, D. Pouessel, 2011, Oncology.

Liver metastases in prostate carcinoma: clinical characteristics and outcome

S. Culine, F. Bibeau, D. Pouessel, 2007, BJU international.

[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

S. Culine, I. Ouzaid, V. Ravery, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

G. Deplanque, S. Oudard, G. Gravis, 2015 .

[Advanced renal carcinomas with special situations. How to treat them?].

J. Patard, S. Culine, D. Pouessel, 2010, Bulletin du cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort

S. Culine, Y. Allory, A. De la taille, 2017, Clinical genitourinary cancer.

Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

S. Chevret, B. Escudier, S. Oudard, 2020 .

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

J. Pastre, P. Laurent-Puig, M. Neri, 2017, BMC Public Health.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

A. Ravaud, P. Caron, D. Pouessel, 2017, European journal of cancer.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

D. Pouessel, C. Chevreau, F. Puisset, 2020, European Journal of Clinical Pharmacology.

Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort.

F. Ducray, D. Figarella-Branger, C. Dehais, 2021, The oncologist.

Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel

S. Culine, D. Pouessel, 2006, Expert review of anticancer therapy.

Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy

Y. Lotan, Y. Allory, F. Radvanyi, 2023, BJU international.

Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

S. Culine, G. Romieu, J. Droz, 2013, Journal of geriatric oncology.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

J. Mosser, H. Blons, J. Merlio, 2017 .

[Angiogenesis targeting in renal carcinomas].

S. Culine, D. Pouessel, 2007, Bulletin du Cancer.

OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study

O. Molinier, G. Zalcman, P. Dumont, 2017 .

Hypofractionated Stereotactic Re-irradiation and  Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results

E. Uro-Coste, D. Pouessel, S. Ken, 2023, The Oncologist.

Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function

S. Culine, D. Pouessel, S. Thézénas, 2012, Anti-cancer drugs.

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

A. Italiano, S. Oudard, G. Gravis, 2009, European urology.

[Actualities in prostate cancer in ASCO annual meeting 2010].

S. Culine, D. Pouessel, D. Pouessel, 2010, Bulletin du cancer.

To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience

S. Culine, D. Pouessel, J. Misset, 2016, Pathology & Oncology Research.

[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].

S. Culine, X. Rébillard, D. Pouessel, 2006, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2023, Journal of Clinical Oncology.

Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.

N. Agarwal, C. Sternberg, P. Grivas, 2023, Journal of Clinical Oncology.